Biocon cash flow

Latest FY26

Cash from operations: ₹1,994cr−50.9% on FY25
Capital spending: ₹1,912cr−18.4% on FY25
Free cash flow: ₹82.3cr−95.2% on FY25
Cash from financing: −₹924cr−₹1,854 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	1,957	1,687	1,569	1,113
	—	990	897	974	419
	—	−115	−109	0.0	−112
	—	0.0	−2.8	0.0	0.0
	—	−163	41.5	−632	60.8
	—	164	137	101	138
	—	−39.7	−57.6	−105	97.1
	—	79.9	44.7	595	−161
	—	104	−1,057	−67.4	−36.4
	—	−55.2	130	0.0	0.0
	—	−918	−0.3	−886	886
	—	624	548	−2,417	1,591
	—	−647	−206	−268	758
	—	−192	581	2,937	−3,736
Cash from operating activities
	479	448	1,887	1,609	1,064
	—	1,789	2,634	1,798	1,017
	—	2,237	4,521	3,408	2,081
	—	0.0	0.0	−161	0.0
	—	243	460	292	229
	—	1,994	4,061	2,954	1,853
Cash from investing activities
	—	1,798	2,137	1,681	1,596
	—	114	207	251	130
	—	0.0	0.0	23.3	3.1
	—	0.0	0.3	0.0	0.0
	—	0.0	0.0	0.0	15,665
	—	0.0	1,825	0.0	3,447
	—	0.0	0.0	553	0.0
	—	0.0	2.8	0.0	0.0
	—	148	114	145	123
	—	−318	167	1,312	−465
	—	−2,082	−234	−1,005	−14,282
Cash from financing activities
	—	8,531	0.5	0.0	1,237
	—	70.4	9.9	30.7	29.5
	—	0.0	0.0	0.0	64.7
	—	5,800	0.0	0.0	0.0
	—	0.0	0.0	800	0.0
	—	301	10,343	697	12,444
	—	2,708	9,770	2,768	28.1
	—	90.9	139	41.8	0.0
	—	—	—	0.0	11.4
	—	865	634	847	486
	—	90.8	82.9	203	71.8
	—	−271	−1,581	0.0	0.0
	—	−924	−1,854	−2,333	13,049
	—	−1,012	1,973	−383	619
	—	199	31.2	2.9	21.7
	—	−812	2,004	−380	641
	—	2,112	2,924	920	1,295
Reference items
	3,536	3,455	3,166	3,299	2,512
	20.4%	20.4%	20.8%	22.4%	22.5%
	82.3	82.3	1,718	1,022	126
	—	−3,714	3,110	−1,866	—
	₹0.51	₹0.51	₹10.60	₹6.31	₹0.78
	690.75×	—	—	—	—
	—	5.41×	2.84×	2.28×	2.88×
	—	243	460	292	229
	—	865	634	847	486

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BIOCON₹350.70

Biocon Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY SYNGENE MANKIND GLENMARK LAURUSLABS ALKEM LUPINMcap ₹56,848 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	1,113.1	1,568.8	1,687.0	1,956.7	—
+ Finance Costs	419.0	974.4	897.4	990.3	—
+ Interest Income	-112.4	0.0	-108.7	-115.4	—
+ Dividend Income	0.0	0.0	-2.8	0.0	—
+ Fair Value (Gains) / Losses	60.8	-632.2	41.5	-163.2	—
+ Share-based Payments	137.6	100.6	137.0	163.9	—
+ Unrealised FX (Gain) / Loss	97.1	-105.4	-57.6	-39.7	—
+ Other Non-cash Items	-160.8	594.5	44.7	79.9	—
+ Other — Cash Effects are Investing / Financing	-36.4	-67.4	-1,057.3	103.6	—
+ Other Reconciling Items	0.0	0.0	130.0	-55.2	—
Changes in Working Capital
+ Inventories	886.2	-886.4	-0.3	-917.8	—
+ Trade Receivables — Current	1,590.5	-2,417.4	548.2	624.4	—
+ Other Current Assets	758.2	-267.9	-205.7	-647.1	—
+ Trade Payables — Current	-3,735.9	2,936.5	580.8	-191.7	—
Cash from Operating Activities
Profit Before Tax (per I/S)	1,064.1	1,609.4	1,886.6	447.9	478.6
+ Total Adjustments (incl. Working Capital)	1,017.0	1,798.1	2,634.2	1,788.7	—
Cash from Operations (pre-tax)	2,081.1	3,407.5	4,520.8	2,236.6	—
+ Interest Received — Operating	0.0	-161.3	0.0	0.0	—
+ Income Taxes Paid	228.6	292.3	459.6	242.6	—
Cash from Operating Activities	1,852.5	2,953.9	4,061.2	1,994.0	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	1,596.0	1,680.5	2,136.6	1,797.9	—
+ Acq of Intangible Assets	130.3	251.1	206.7	113.8	—
+ Disp of Fixed Assets	3.1	23.3	0.0	0.0	—
+ Disp of Investment Property	0.0	0.0	0.3	0.0	—
+ Acq of Other Long-term Assets	15,664.5	0.0	0.0	0.0	—
+ Sale of Investments (Equity / Debt)	3,447.4	0.0	1,825.2	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	553.2	0.0	0.0	—
+ Dividends Received — Investing	0.0	0.0	2.8	0.0	—
+ Interest Received — Investing	123.3	144.6	114.4	148.0	—
+ Other Inflows / (Outflows) — Investing	-464.8	1,312.4	166.5	-318.4	—
Cash from Investing Activities	-14,281.8	-1,004.5	-234.1	-2,082.1	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	1,236.8	0.0	0.5	8,531.1	—
+ Proceeds from Exercise of Stock Options	29.5	30.7	9.9	70.4	—
+ Buyback / Redemption of Own Shares	64.7	0.0	0.0	0.0	—
+ Payments — Change in Ownership of Subsidiaries	0.0	0.0	0.0	5,800.2	—
+ Proceeds from Debentures / Notes / Bonds	0.0	800.0	0.0	0.0	—
+ Proceeds from Borrowings	12,444.0	696.6	10,342.8	301.3	—
+ Repayment of Borrowings	28.1	2,767.8	9,769.9	2,707.9	—
+ Payment of Lease Liabilities	0.0	41.8	138.8	90.9	—
+ Payment of Finance Lease Liabilities	11.4	0.0	—	—	—
+ Interest Paid	485.6	847.4	634.2	865.4	—
+ Dividends Paid	71.8	203.0	82.9	90.8	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	-1,581.4	-271.2	—
Cash from Financing Activities	13,048.7	-2,332.7	-1,854.0	-923.6	—
Net Changes in Cash (pre-FX)	619.4	-383.3	1,973.1	-1,011.7	—
+ Effect of FX Rate Changes on Cash	21.7	2.9	31.2	199.4	—
Net Changes in Cash	641.1	-380.4	2,004.3	-812.3	—
Closing Cash	1,294.8	919.5	2,923.8	2,111.5	—
Reference Items
EBITDA	2,511.7	3,298.7	3,166.3	3,455.3	3,536.4
EBITDA Margin %	22.48	22.36	20.75	20.41	20.42
Free Cash Flow (CFO − Capex)	126.2	1,022.3	1,717.9	82.3	82.3
Free Cash Flow to Equity	—	-1,866.2	3,109.6	-3,713.9	—
Free Cash Flow per Basic Share	0.78	6.31	10.60	0.51	0.51
Price to Free Cash Flow	—	—	—	—	690.75
Cash Flow to Net Income	2.88	2.28	2.84	5.41	—
Cash Paid for Taxes	228.6	292.3	459.6	242.6	—
Cash Paid for Interest	485.6	847.4	634.2	865.4	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.